Thats true, but LCT have been quite clever here and made the primary endpoint safety and the secondary endpoint efficacy.
So even now I am sure the study would be able to claim a successful primary endpoint. It will be a "successful" trial. But the real area of interest is going to be efficacy.
Passing Through the 20's, page-128
-
- There are more pages in this discussion • 51 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add 1AI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $11.81M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.7¢ | 0.6¢ | $41.21K | 6.825M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 3056700 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 913000 | 5 |
View Market Depth
| Last trade - 15.36pm 27/09/2024 (20 minute delay) ? |
| 1AI (ASX) Chart |